Hims & Hers Health (HIMS) to Release Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results after the market closes on Monday, May 5th. Analysts expect Hims & Hers Health to post earnings of $0.11 per share and revenue of $535.21 million for the quarter. Hims & Hers Health has set its Q1 2025 guidance at EPS and its FY 2025 guidance at EPS.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Stock Up 13.3 %

NYSE HIMS traded up $4.82 during trading on Friday, hitting $40.98. The company's stock had a trading volume of 49,512,288 shares, compared to its average volume of 16,802,829. Hims & Hers Health has a 52 week low of $11.45 and a 52 week high of $72.98. The firm has a market cap of $9.10 billion, a P/E ratio of 93.14 and a beta of 1.65. The firm has a 50 day moving average price of $32.21 and a 200 day moving average price of $31.49.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the sale, the chief executive officer now owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 4,153 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $35.30, for a total value of $146,600.90. Following the completion of the transaction, the insider now directly owns 161,497 shares in the company, valued at $5,700,844.10. The trade was a 2.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 666,234 shares of company stock worth $26,387,645 over the last three months. Company insiders own 17.71% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on HIMS shares. Piper Sandler boosted their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 25th. Bank of America boosted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday. Citigroup reduced their target price on shares of Hims & Hers Health from $27.00 to $25.00 and set a "sell" rating for the company in a research note on Friday, April 25th. Truist Financial lowered their price target on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Finally, Needham & Company LLC lifted their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, Hims & Hers Health currently has an average rating of "Hold" and an average price target of $36.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.